RxDoctor Payments Data

Rollington Ferguson, MD

Cardiovascular Disease · Oakland, CANPI 1962582189

Payments from drug & device makers

$1,284in general payments, 2019–2025

Across 64 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$158
  • AstraZeneca$145
  • Novo Nordisk$139
  • Boehringer Ingelheim$120
  • Actelion Pharmaceuticals US, Inc.$103
  • E.r. Squibb & Sons, L.L.C.$102
  • plus $516 from 11 others

What the payments were for

  • Food & beverage$1,02380%
  • Education$26120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,284 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$218,789
Medicare patients
385
Services billed
1,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin236$235,779
EliquisApixaban305$231,193
TradjentaLinagliptin100$79,717
XareltoRivaroxaban34$43,708
MyrbetriqMirabegron79$41,644
EntrestoSacubitril/Valsartan42$40,967
OzempicSemaglutide18$20,262
Combivent RespimatIpratropium/Albuterol Sulfate26$17,754
JanuviaSitagliptin Phosphate22$15,731
FarxigaDapagliflozin Propanediol17$15,228
LinzessLinaclotide28$14,587
LokelmaSodium Zirconium Cyclosilicate17$12,316
Quinidine Sulfate16$12,224
XanaxAlprazolam12$9,145
Bumetanide196$8,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$120$333,249362 claims
PfizerEliquis, Prempro$64$234,588318 claims
Johnson & JohnsonXarelto$91$43,70834 claims
NovartisEntresto$158$40,96742 claims
AstraZenecaFarxiga, Lokelma, Symbicort$145$31,32048 claims
Novo NordiskOzempic$139$20,26218 claims
MerckJanuvia$82$15,73122 claims
AbbVieLinzess$18$14,58728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →